Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce ...

Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the vital role MRNA technology played in COVID-19 vaccines. Subscribe to our ...

Scientists developed a new mRNA platform that keeps vaccines and therapies effective in older adults and patients with obesity, where current treatments often lose potency.

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.

Add Yahoo as a preferred source to see more of our stories on Google. The United States is turning its back on what could be the greatest medical advance in a generation — vaccines made with messenger ...

Read more about Future pandemics may be fought faster with mRNA and advanced vaccine platforms on Devdiscourse ...

BioNTech's co-founders Ugur Sahin and Oezlem Tuereci plan to leave the company by 2026 to establish a new venture focused on mRNA technology. While ensuring BioNTech's existing operations continue ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. recently terminated $500 million in federal funding for developing mRNA vaccines, but don’t be fooled into thinking these life-saving ...

Few medical advances in recent memory have sparked as much controversy as COVID-19 vaccines utilizing mRNA (messenger RNA). Currently, there are two such vaccines, from Pfizer-BioNTech and Moderna.

Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology, the company said.